GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nevro Corp (FRA:1N7) » Definitions » Debt-to-Revenue

Nevro (FRA:1N7) Debt-to-Revenue : 0.64 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Nevro Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Nevro's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €34.2 Mil. Nevro's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €188.0 Mil. Nevro's annualized Revenue for the quarter that ended in Sep. 2024 was €349.3 Mil. Nevro's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.64.


Nevro Debt-to-Revenue Historical Data

The historical data trend for Nevro's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nevro Debt-to-Revenue Chart

Nevro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 0.90 0.43 0.49 0.51

Nevro Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.47 0.54 0.58 0.64

Competitive Comparison of Nevro's Debt-to-Revenue

For the Medical Devices subindustry, Nevro's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nevro's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nevro's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nevro's Debt-to-Revenue falls into.



Nevro Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Nevro's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 198.168) / 389.885
=0.51

Nevro's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(34.153 + 188.025) / 349.264
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Nevro Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nevro's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nevro Business Description

Traded in Other Exchanges
Address
1800 Bridge Parkway, Redwood City, CA, USA, 94065
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

Nevro Headlines

No Headlines